| Cat.No. | Name | Information |
|---|---|---|
| M1721 | AZD4547 | AZD4547 (Fexagratinib) is a potent, selective and orally active pan-FGFR inhibitor with IC50s of 0.2. 2.5, 1.8 and 165 nM for FGFR1, 2, 3 and 4, respectively. |
| M1840 | BGJ398 (Infigratinib) | BGJ398 (Infigratinib) is a potent and selective FGFR kinase inhibitor with IC50 values of 0.9 nM, 1.4 nM, 1 nM and 60 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. |
| M9715 | Erdafitinib | Erdafitinib (JNJ-42756493) is a potent and selective orally bioavailable, pan FGFR inhibitor with potential antineoplastic activity. |
| M1875 | PD173074 | PD173074 is a selective FGFR1 and FGFR3 inhibitor with IC50 values of 5, 21.5, ~100, 17600 and 19800 nM for FGFR3, FGFR1, VEGFR2, PDGFR and c-Src respectively. |
| M54591 | SAR-442501 | SAR-442501 is a novel anti-FGFR3 monoclonal antibody for studies related to achondroplasia (ACH). |
| M54590 | TYRA-200 | TYRA-200 is an FGFR1/2/3 (FGFR2 mutation) inhibitor. |
| M54589 | TYRA-300 | TYRA-300 is an orally active, selective FGFR3 inhibitor for the study of chondrodysplasia. |
| M54477 | VSPPLTLGQLLS | VSPPLTLGQLLS is a small peptide FGFR3 inhibitor, peptide P3, inhibits FGFR3 phosphorylation. |
| M45218 | ABSK061 | ABSK061 is an orally active, selective, small molecule FGFR2/3 inhibitor for studies related to solid tumors. |
| M45217 | ABSK121 | ABSK121 is an orally active, highly selective small molecule FGFR inhibitor. |
| M45216 | ABSK012 | ABSK012 is a highly selective FGFR4 inhibitor with antitumor activity for studies related to soft tissue sarcoma (STS). |
| M43509 | S6K2-IN-1 | S6K2-IN-1 is a S6K2 inhibitor (IC50: 22 nM). |
| M43508 | FGFR4-IN-14 | FGFR4-IN-14 is a FGFR4 inhibitor (IC50: 2.4 nM. |
| M43507 | FGFR1 inhibitor-10 | FGFR1 inhibitor-10 is an FGFR1 inhibitor (IC50: 28 nM). |
| M43506 | FGFR1 inhibitor-8 | FGFR1 inhibitor-8 is a FGFR1 inhibitor (IC50s: 0.5 nM). |
| M43505 | Formononetin-d3-1 | Formononetin-d3-1 is the deuterium-labeled Formononetin. |
| M43504 | FGFR1 inhibitor-9 | FGFR1 inhibitor-9 is an FGFR1 inhibitor (IC50s: 0.85 nM). |
| M43503 | FGFR4-IN-16 | FGFR4-IN-16 (CY-15-2) is a covalent inhibitor of FGFR-4 for cancer research. |
| M43502 | FGFR1 inhibitor 7 | FGFR1 inhibitor 7 is an inhibitor of FGFR1 Tyrosine Kinase with IC50 value of 0.33 nM. |
| M43501 | Resigratinib | Resigratinib (KIN-3248) is a FGFR tyrosine kinase inhibitor, with antineoplastic effect. |
| M43500 | LC-MB12 | LC-MB12 is an orally active PROTAC compound targets FGFR2 degradation with a DC50 of 11.8 nM. |
| M43499 | Irpagratinib | Irpagratinib (ABSK011) is a potentially best-in-class, orally active fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor targeting FGFR4 (IC50<10 nM). |
| M40986 | NGM-313 | NGM-313 is a β-Klotho/FGFR1c-targeted monoclonal antibody for studies related to non-alcoholic steatohepatitis (NASH). |
| M40984 | BOS-580 | BOS-580 is an FGF21 analog and modulator for studies related to non-alcoholic steatohepatitis (NASH). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
